Malignant Neoplasms of the Genitourinary System (Including Prostate Cancer) VA disability rating & claim guide

Yes. The VA rates Malignant Neoplasms of the Genitourinary System (Including Prostate Cancer) under VASRD diagnostic code 7528 (Genitourinary System). This code covers malignant neoplasms of the genitourinary system — cancer of the urinary and reproductive organs rated in § 4.115b, prostate cancer among them. An active malignancy under this code is evaluated at 100 percent. Under the code's note, that 100 percent continues after surgical, X-ray, antineoplastic chemotherapy, or other therapeutic treatment ends, with a mandatory VA examination at the expiration of six months. If there has been no local recurrence or metastasis at that point, the evaluation is based on the residuals that remain, rated as voiding dysfunction or renal dysfunction, whichever is predominant.

Possible VA ratings for Malignant Neoplasms of the Genitourinary System (Including Prostate Cancer) are 100%, 80%, 60%, 40%, 30%, 20%, 10%, 0%. Examples: 100%: Malignant neoplasms of the genitourinary system. Under the code's Note the 100 percent evaluation continues following the cessation of surgical, X-ray, antineoplastic chemotherapy or other therapeutic procedure, with a mandatory VA examination at the expiration of six months; any change in evaluation is subject to § 3.105(e). If there has been no local recurrence or metastasis, rate on residuals. The Note rates residuals as voiding dysfunction or renal dysfunction, whichever is predominant; residuals rated as renal dysfunction: chronic kidney disease with glomerular filtration rate (GFR) less than 15 mL/min/1.73 m2 for at least 3 consecutive months during the past 12 months; or requiring regular routine dialysis; or eligible kidney transplant recipient; 80%: Residuals rated as renal dysfunction: chronic kidney disease with GFR from 15 to 29 mL/min/1.73 m2 for at least 3 consecutive months during the past 12 months; 60%: Residuals rated as voiding dysfunction, continual urine leakage, post surgical urinary diversion, urinary incontinence, or stress incontinence: requiring the use of an appliance or the wearing of absorbent materials which must be changed more than 4 times per day; or residuals rated as renal dysfunction: chronic kidney disease with GFR from 30 to 44 mL/min/1.73 m2 for at least 3 consecutive months during the past 12 months.

Vetrify estimates the typical rating awarded for Malignant Neoplasms of the Genitourinary System (Including Prostate Cancer) at around 60%, based on VA claims data and the rating schedule. An estimated 6,200 veterans are service-connected for Malignant Neoplasms of the Genitourinary System (Including Prostate Cancer).

Strong evidence for a Malignant Neoplasms of the Genitourinary System (Including Prostate Cancer) claim includes: Pathology and oncology records establishing the malignant neoplasm and its genitourinary site; Treatment records showing the date surgical, X-ray, antineoplastic chemotherapy, or other therapeutic procedure ended, which is what the six-month clock to the mandatory VA examination runs from; Follow-up imaging and oncology notes addressing whether there has been local recurrence or metastasis; Post-treatment urology records covering the voiding dysfunction measures — appliance or absorbent material use and changes per day, daytime voiding interval, how many times a night the veteran wakes to void, and any catheterization for urinary retention.

Common pitfalls when filing for Malignant Neoplasms of the Genitourinary System (Including Prostate Cancer): Filing only on a prostatectomy or other surgery as though the operation were the subject of this code, when the code covers malignant neoplasms of the genitourinary system and treatment is what the note's six-month sequence starts from; Treating the 100 percent as permanent, when the note schedules a mandatory VA examination at the expiration of six months after treatment ends and makes any change subject to § 3.105(e); Leaving post-treatment residuals undocumented and unclaimed, since after that examination the evaluation is made on residuals rated as voiding dysfunction or renal dysfunction, whichever is predominant.

For some of the cancers this code rates. Only the cancers named below are presumptive, each under its own provision. 38 CFR 3.309(e) names "Prostate cancer" among the diseases associated with herbicide agents, for a veteran exposed to one during service. The regulation presumes that exposure for service in Vietnam, including its offshore waters, from January 9, 1962 to May 7, 1975; in a unit that, as the Department of Defense determined, operated in or near the Korean DMZ where herbicides were applied, from April 1, 1968 to August 31, 1971; or, in the Air Force or Air Force Reserve, regularly and repeatedly aboard C-123 aircraft used to spray herbicides (38 CFR 3.307(a)(6)). The statute, 38 U.S.C. 1116, 1116A and 1116B, also covers U.S. or Royal Thai bases in Thailand, Laos, Mimot or Krek in Cambodia, Guam or American Samoa or their territorial waters, Johnston Atoll or a ship that called there, and the DMZ from September 1, 1967, each in its own period. 38 CFR 3.309(f) names "Kidney cancer" and "Bladder cancer" among the diseases associated with the water supply at Camp Lejeune, for a veteran, former reservist or member of the National Guard with at least 30 days of service in total, consecutive or not, at Camp Lejeune or Marine Corps Air Station New River between August 1, 1953 and December 31, 1987 (38 CFR 3.307(a)(7)). 38 CFR 3.309(d) names "Cancer of the urinary tract" among the diseases specific to radiation-exposed veterans, whom 38 CFR 3.309(d)(3) defines by radiation-risk activity, such as onsite participation in an atmospheric nuclear test or the occupation of Hiroshima or Nagasaki from August 6, 1945 to July 1, 1946. 38 U.S.C. 1116(a)(2) names "Bladder cancer" among the diseases associated with herbicide agents, for a veteran with covered service under 38 U.S.C. 1116(d), 1116A or 1116B: Vietnam and its offshore waters, U.S. or Royal Thai bases in Thailand, Laos, Mimot or Krek in Cambodia, Guam or American Samoa or their territorial waters, Johnston Atoll or a ship that called there, and in or near the Korean DMZ, each in its own period. 38 CFR 3.309(e) does not name it in its August 1, 2026 edition; the statute does. 38 U.S.C. 1120(b) names "Kidney cancer" and "Reproductive cancer of any type" for a covered veteran: one who, on or after August 2, 1990, was assigned to a duty station in, or in the airspace above, Bahrain, Iraq, Kuwait, Oman, Qatar, Saudi Arabia, Somalia or the United Arab Emirates, or, on or after September 11, 2001, Afghanistan, Djibouti, Egypt, Jordan, Lebanon, Syria, Yemen or Uzbekistan (38 U.S.C. 1119(c)). VA's list of presumptive cancers related to burn pit exposure names "Urinary bladder cancer (including overlapping sites of the bladder)", "Ureter cancer (including the uretic orifice, urachus)" and "Prostate cancer" for a covered veteran of the Gulf War or post-9/11 service (38 U.S.C. 1119(c)): VA's own reading of 38 U.S.C. 1120(b), and by VA's note not a complete list. Each presumption gives way to affirmative evidence to the contrary (38 CFR 3.307(d); 38 U.S.C. 1113).

Conditions that can be service-connected as secondary to Malignant Neoplasms of the Genitourinary System (Including Prostate Cancer), when a medical opinion links them, include: Erectile dysfunction; Depression. A secondary condition gets its own rating, which VA combines with the veteran's other ratings under 38 CFR 4.25.